Antibody response to pseudomonas aeruginosa in children with cystic fibrosis

Pediatric Pulmonology

Volumn 44, Issue 4, 2009, Pages 392-401

  Milagres, Lucimar G ^a   Castro, Tatiana L A ^a   Garcia, Daniely ^a   Cruz, Aline C ^a   Higa, Laurinda ^b   Folescu, Tama ^b   Marques, Elizabeth A ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Antibody testing; Cystic fibrosis; P. aeruginosa lung infection; Pseudomonas serology; Type III Secretion System

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL PROTEIN; PROTEIN ANTIBODY; PROTEIN PCRV; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; AGE DISTRIBUTION; ANTIBODY RESPONSE; ARTICLE; BACTERIUM CULTURE; BLOOD SAMPLING; CELL LYSATE; CHILD; CHRONIC DISEASE; CONTROLLED STUDY; CYSTIC FIBROSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SCHOOL CHILD; SPUTUM ANALYSIS;

ADOLESCENT; ANTIBODIES, BACTERIAL; BRAZIL; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; CYSTIC FIBROSIS; EARLY DIAGNOSIS; FEMALE; HUMANS; INFANT; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; REFERENCE VALUES;

EID: 66149127595     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21022     Document Type: Article

References (24)

1. Frederiksen B, Koch C, Hoiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol 1999; 28: 156-166.
2. Cabello GM, Moreira AF, Horovitz D, Correia P, Santa Rosa A, Llerena J, Jr., Greg J, Grody WW, Degrave WM, Fernandes O, Cabello PH. Cystic fibrosis: low frequency of DF508 mutation in 2 population samples from Rio de Janeiro, Brazil. Hum Biol 1999;71: 189-196.
3. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, Drumm ML, Iannuzzi MC, Collins FS, Tsui LC. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245: 1066-1073.
4. Li Z, Kosorok MR, Farrell PM, Laxova A, West SEH, Green CG, Collins J, Rock MJ, Splaingard ML. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005;293: 581-588.
5. Ratjen F, Walter H, Haug M, Meisner C, Grasemann H, Dtiring G. Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients. Pediatr Pulmonol 2007;42: 249-255.
6. West SE, Zeng L, Lee BL, Kosorok MR, Laxova ABS, Rock MJ, Splaingard MJ, Farrell PM. Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors. JAMA 2002;287: 2958-2967.
7. Tramper-Stranders GA, van der Ent CK, Wolfs TFW. Detection of Pseudomonas aeruginosa in patients with cystic fibrosis. J Cyst Fibros 2005;4: 37-43.
8. Corech R, Rao A, Laxova A, Moss J, Rock MJ, Li Z, Kosorok MR, Splaingard ML, Farrel PM, Barbieri JT. Early immune response to the components of the type III system of Pseudomonas aeruginosa in children with cystic fibrosis. J Clin Microbiol 2005;43: 3956-3962.
9. Kappler M, Kraxner A, Reinhardt D, Ganster B, Griese M, Lang T. Diagnostic and prognostic value of serum antibodies against Pseudomonas aeruginosa in cystic fibrosis. Thorax 2006;61: 684-688.
10. Tamper-Stranders GA, van der Ent CK, Sliaker MG, Terheggen- Lagro SWJ, Teding F, Kimpen JLL, Wolfs TF. Diagnostic value of serological tests against Pseudomonas aeruginosa in a large cystic fibrosis population. Thorax 2006;61: 689-693.
11. Doring G, Conway SP, Heijerman HGM, Hodson ME, Hoiby N, Smyth A, Touw DJ. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000;16: 749-767.
12. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23: 330-335.
13. Blonder-Hill E, Henry DA, Speert DP. Pseudomonas. In: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, editors. Manual of clinical microbiology. 9th edition. Washington DC: ASM Press; 2007. pp. 734-802.
14. Sawa T, Yahr T, Ohara M, Kurahashi K, Gropper MA, Wiener- Kronish JP, Frank DW. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat Med 1999;5: 392-398.
15. Rodrigues JC, Cardieri JMA, Bussamra MHCF, Nakaie CMA, Almeida MB, Silva Filho LVF, Adde FV. Provas de funcao pulmonar em criancas e adolescentes. J Pneumol 2002;28: S207-S221.
16. Hoiby N. Antibodies against Pseudomonas aeruginosa in serum from normal persons and patients colonized with mucoid or non- mucoid P. aeruginosa: results obtained by crossed immunoelec- trophoresis. APMIS 1977;85: 142-148.
17. Goure J, Pastor A, Faudry E, Chabert J, Dessen A, Attree I. The V antigen of Pseudomonas aeruginosa is required for assembly of the functional PopB/PopD translocation pore in host cell membranes. Infect Immun 2004;72: 4741-4750.
18. Brett MM, Ghoneim ATM, Littlewood JM. Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis. Arch Dis Child 1986;61: 1114-1120.
19. Kosorok MR, Zeng L, West SE, Rock MJ, Splaingard ML, Laxova A, Green CG, Collins J, Farrel PM. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001;32: 277-287.
20. Johansen HK, Norregaard L, Gotzsche PC, Pressler T, Koch C, Hoiby N. Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: a marker of therapeutic success? A 30- year cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection. Pediatr Pulmonol 2004;37: 427-432.
21. Farrel PM, Govan JRW. Pseudomonas serology: confusion, controversy, and challenge. Thorax 2006;61: 645-647.
22. Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M, Hiatt P, McCoy K, Castile R, Smith AL, Ramsey BW. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001;183: 444-452.
23. Ratjen F, Doring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001;358: 983-984.
24. Treggiari MM, Rosenfeld M, Retsch-Bogart G, Gibson R, Ramsey B. Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Pediatr Pulmonol 2007;42: 751-756.